{
 "cells": [
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Preprocessing of Age Attributes of COVID-19 Clinical Trials Data"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Questions to ask regarding the age attribute:\n",
    "1. What is the distribution of age groups?\n",
    "2. Among the top countries with the most clincal trials, what is the age group distribution?"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Warning message:\n",
      "\"package 'dplyr' was built under R version 3.6.3\"\n",
      "Attaching package: 'dplyr'\n",
      "\n",
      "The following objects are masked from 'package:stats':\n",
      "\n",
      "    filter, lag\n",
      "\n",
      "The following objects are masked from 'package:base':\n",
      "\n",
      "    intersect, setdiff, setequal, union\n",
      "\n",
      "Warning message:\n",
      "\"package 'tidyverse' was built under R version 3.6.3\"-- Attaching packages --------------------------------------- tidyverse 1.3.0 --\n",
      "v ggplot2 3.3.3     v purrr   0.3.4\n",
      "v tibble  3.0.4     v stringr 1.4.0\n",
      "v tidyr   1.1.2     v forcats 0.5.0\n",
      "v readr   1.4.0     \n",
      "Warning message:\n",
      "\"package 'ggplot2' was built under R version 3.6.3\"Warning message:\n",
      "\"package 'tibble' was built under R version 3.6.3\"Warning message:\n",
      "\"package 'tidyr' was built under R version 3.6.3\"Warning message:\n",
      "\"package 'readr' was built under R version 3.6.3\"Warning message:\n",
      "\"package 'purrr' was built under R version 3.6.3\"Warning message:\n",
      "\"package 'stringr' was built under R version 3.6.3\"Warning message:\n",
      "\"package 'forcats' was built under R version 3.6.3\"-- Conflicts ------------------------------------------ tidyverse_conflicts() --\n",
      "x dplyr::filter() masks stats::filter()\n",
      "x dplyr::lag()    masks stats::lag()\n",
      "Warning message:\n",
      "\"package 'viridis' was built under R version 3.6.3\"Loading required package: viridisLite\n",
      "Warning message:\n",
      "\"package 'viridisLite' was built under R version 3.6.3\""
     ]
    }
   ],
   "source": [
    "# load library\n",
    "library(dplyr)\n",
    "library(tidyverse)\n",
    "library(viridis)\n",
    "library(ggplot2)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<table>\n",
       "<thead><tr><th scope=col>X</th><th scope=col>Title</th><th scope=col>Status</th><th scope=col>Interventions</th><th scope=col>Gender</th><th scope=col>Age</th><th scope=col>Phases</th><th scope=col>Enrollment</th><th scope=col>Start.Date</th><th scope=col>Completion.Date</th><th scope=col>Last.Update.Posted</th><th scope=col>Locations</th><th scope=col>URL</th><th scope=col>MapCountry</th><th scope=col>Drugonly</th></tr></thead>\n",
       "<tbody>\n",
       "\t<tr><td>1                                                                                                                </td><td>Duvelisib to Combat COVID-19                                                                                     </td><td>Recruiting                                                                                                       </td><td>Drug: Duvelisib|Procedure: Peripheral blood draw|Drug: Placebo                                                   </td><td>All                                                                                                              </td><td>18 Years and older Â  (Adult, Older Adult)                                                                       </td><td>Phase 2                                                                                                          </td><td> 28                                                                                                              </td><td>October 12, 2020                                                                                                 </td><td>April 30, 2022                                                                                                   </td><td>November 9, 2020                                                                                                 </td><td>Washington University School of Medicine, Saint Louis, Missouri, United States                                   </td><td>https://ClinicalTrials.gov/show/NCT04372602                                                                      </td><td>United States                                                                                                    </td><td>Duvelisib|Placebo                                                                                                </td></tr>\n",
       "\t<tr><td>2                                                                                                                </td><td>Observational Cohort of COVID-19 Patients at Raymond-Poincare                                                    </td><td>Recruiting                                                                                                       </td><td>                                                                                                                 </td><td>All                                                                                                              </td><td>18 Years and older Â  (Adult, Older Adult)                                                                       </td><td>                                                                                                                 </td><td>500                                                                                                              </td><td>May 7, 2020                                                                                                      </td><td>June 2020                                                                                                        </td><td>May 14, 2020                                                                                                     </td><td>Department of Infectiology, Raymond PoincarÃ© Hospital, APHP, Garches, France                                    </td><td>https://ClinicalTrials.gov/show/NCT04364698                                                                      </td><td>France                                                                                                           </td><td>                                                                                                                 </td></tr>\n",
       "\t<tr><td>3                                                                                                                </td><td>Decitabine for Coronavirus (COVID-19) Pneumonia- Acute Respiratory Distress Syndrome (ARDS) Treatment: DART Trial</td><td>Recruiting                                                                                                       </td><td>Drug: Decitabine|Other: Placebo Saline                                                                           </td><td>All                                                                                                              </td><td>18 Years and older Â  (Adult, Older Adult)                                                                       </td><td>Phase 2                                                                                                          </td><td> 40                                                                                                              </td><td>September 14, 2020                                                                                               </td><td>July 2021                                                                                                        </td><td>September 25, 2020                                                                                               </td><td>Johns Hopkins University, Baltimore, Maryland, United States                                                     </td><td>https://ClinicalTrials.gov/show/NCT04482621                                                                      </td><td>United States                                                                                                    </td><td>Decitabine                                                                                                       </td></tr>\n",
       "\t<tr><td>4                                                                                                                </td><td>COVID-19 Surveillance Based on Smart Wearable Device                                                             </td><td>Not yet recruiting                                                                                               </td><td>                                                                                                                 </td><td>All                                                                                                              </td><td>18 Years to 75 Years Â  (Adult, Older Adult)                                                                     </td><td>                                                                                                                 </td><td>200                                                                                                              </td><td>July 1, 2020                                                                                                     </td><td>March 10, 2021                                                                                                   </td><td>July 7, 2020                                                                                                     </td><td>Peking University First Hospital, Beijing, Beijing, China                                                        </td><td>https://ClinicalTrials.gov/show/NCT04459637                                                                      </td><td>China                                                                                                            </td><td>                                                                                                                 </td></tr>\n",
       "\t<tr><td>5                                                                                                                </td><td>A Phase 2 Trial of Infliximab in Coronavirus Disease 2019 (COVID-19).                                            </td><td>Recruiting                                                                                                       </td><td>Drug: Infliximab                                                                                                 </td><td>All                                                                                                              </td><td>18 Years and older Â  (Adult, Older Adult)                                                                       </td><td>Phase 2                                                                                                          </td><td> 17                                                                                                              </td><td>June 1, 2020                                                                                                     </td><td>December 2020                                                                                                    </td><td>June 11, 2020                                                                                                    </td><td>Tufts Medical Center, Boston, Massachusetts, United States                                                       </td><td>https://ClinicalTrials.gov/show/NCT04425538                                                                      </td><td>United States                                                                                                    </td><td>Infliximab                                                                                                       </td></tr>\n",
       "\t<tr><td>6                                                                                                                                                            </td><td><span style=white-space:pre-wrap>Safety &amp; Performance Evaluation of Seraph 100 in Treatment of Pts With COVID-19                                  </span></td><td>Not yet recruiting                                                                                                                                           </td><td><span style=white-space:pre-wrap>Device: Seraph 100                                            </span>                                                       </td><td>All                                                                                                                                                          </td><td>18 Years to 90 Years Â  (Adult, Older Adult)                                                                                                                 </td><td>Not Applicable                                                                                                                                               </td><td> 42                                                                                                                                                          </td><td>December 15, 2020                                                                                                                                            </td><td>April 15, 2021                                                                                                                                               </td><td>November 27, 2020                                                                                                                                            </td><td><span style=white-space:pre-wrap>Carla Kikken-Jussen, Vaals, Limburg, Netherlands                              </span>                                       </td><td>https://ClinicalTrials.gov/show/NCT04547257                                                                                                                  </td><td><span style=white-space:pre-wrap>Netherlands  </span>                                                                                                        </td><td><span style=white-space:pre-wrap>                 </span>                                                                                                    </td></tr>\n",
       "</tbody>\n",
       "</table>\n"
      ],
      "text/latex": [
       "\\begin{tabular}{r|lllllllllllllll}\n",
       " X & Title & Status & Interventions & Gender & Age & Phases & Enrollment & Start.Date & Completion.Date & Last.Update.Posted & Locations & URL & MapCountry & Drugonly\\\\\n",
       "\\hline\n",
       "\t 1                                                                                                                 & Duvelisib to Combat COVID-19                                                                                      & Recruiting                                                                                                        & Drug: Duvelisib\\textbar{}Procedure: Peripheral blood draw\\textbar{}Drug: Placebo                                & All                                                                                                               & 18 Years and older Â  (Adult, Older Adult)                                                                        & Phase 2                                                                                                           &  28                                                                                                               & October 12, 2020                                                                                                  & April 30, 2022                                                                                                    & November 9, 2020                                                                                                  & Washington University School of Medicine, Saint Louis, Missouri, United States                                    & https://ClinicalTrials.gov/show/NCT04372602                                                                       & United States                                                                                                     & Duvelisib\\textbar{}Placebo                                                                                      \\\\\n",
       "\t 2                                                                                                                 & Observational Cohort of COVID-19 Patients at Raymond-Poincare                                                     & Recruiting                                                                                                        &                                                                                                                   & All                                                                                                               & 18 Years and older Â  (Adult, Older Adult)                                                                        &                                                                                                                   & 500                                                                                                               & May 7, 2020                                                                                                       & June 2020                                                                                                         & May 14, 2020                                                                                                      & Department of Infectiology, Raymond PoincarÃ© Hospital, APHP, Garches, France                                     & https://ClinicalTrials.gov/show/NCT04364698                                                                       & France                                                                                                            &                                                                                                                  \\\\\n",
       "\t 3                                                                                                                 & Decitabine for Coronavirus (COVID-19) Pneumonia- Acute Respiratory Distress Syndrome (ARDS) Treatment: DART Trial & Recruiting                                                                                                        & Drug: Decitabine\\textbar{}Other: Placebo Saline                                                                  & All                                                                                                               & 18 Years and older Â  (Adult, Older Adult)                                                                        & Phase 2                                                                                                           &  40                                                                                                               & September 14, 2020                                                                                                & July 2021                                                                                                         & September 25, 2020                                                                                                & Johns Hopkins University, Baltimore, Maryland, United States                                                      & https://ClinicalTrials.gov/show/NCT04482621                                                                       & United States                                                                                                     & Decitabine                                                                                                       \\\\\n",
       "\t 4                                                                                                                 & COVID-19 Surveillance Based on Smart Wearable Device                                                              & Not yet recruiting                                                                                                &                                                                                                                   & All                                                                                                               & 18 Years to 75 Years Â  (Adult, Older Adult)                                                                      &                                                                                                                   & 200                                                                                                               & July 1, 2020                                                                                                      & March 10, 2021                                                                                                    & July 7, 2020                                                                                                      & Peking University First Hospital, Beijing, Beijing, China                                                         & https://ClinicalTrials.gov/show/NCT04459637                                                                       & China                                                                                                             &                                                                                                                  \\\\\n",
       "\t 5                                                                                                                 & A Phase 2 Trial of Infliximab in Coronavirus Disease 2019 (COVID-19).                                             & Recruiting                                                                                                        & Drug: Infliximab                                                                                                  & All                                                                                                               & 18 Years and older Â  (Adult, Older Adult)                                                                        & Phase 2                                                                                                           &  17                                                                                                               & June 1, 2020                                                                                                      & December 2020                                                                                                     & June 11, 2020                                                                                                     & Tufts Medical Center, Boston, Massachusetts, United States                                                        & https://ClinicalTrials.gov/show/NCT04425538                                                                       & United States                                                                                                     & Infliximab                                                                                                       \\\\\n",
       "\t 6                                                                                                                   & Safety \\& Performance Evaluation of Seraph 100 in Treatment of Pts With COVID-19                                   & Not yet recruiting                                                                                                  & Device: Seraph 100                                                                                                  & All                                                                                                                 & 18 Years to 90 Years Â  (Adult, Older Adult)                                                                        & Not Applicable                                                                                                      &  42                                                                                                                 & December 15, 2020                                                                                                   & April 15, 2021                                                                                                      & November 27, 2020                                                                                                   & Carla Kikken-Jussen, Vaals, Limburg, Netherlands                                                                    & https://ClinicalTrials.gov/show/NCT04547257                                                                         & Netherlands                                                                                                         &                                                                                                                    \\\\\n",
       "\\end{tabular}\n"
      ],
      "text/markdown": [
       "\n",
       "| X | Title | Status | Interventions | Gender | Age | Phases | Enrollment | Start.Date | Completion.Date | Last.Update.Posted | Locations | URL | MapCountry | Drugonly |\n",
       "|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|\n",
       "| 1                                                                                                                 | Duvelisib to Combat COVID-19                                                                                      | Recruiting                                                                                                        | Drug: Duvelisib|Procedure: Peripheral blood draw|Drug: Placebo                                                    | All                                                                                                               | 18 Years and older Â  (Adult, Older Adult)                                                                        | Phase 2                                                                                                           |  28                                                                                                               | October 12, 2020                                                                                                  | April 30, 2022                                                                                                    | November 9, 2020                                                                                                  | Washington University School of Medicine, Saint Louis, Missouri, United States                                    | https://ClinicalTrials.gov/show/NCT04372602                                                                       | United States                                                                                                     | Duvelisib|Placebo                                                                                                 |\n",
       "| 2                                                                                                                 | Observational Cohort of COVID-19 Patients at Raymond-Poincare                                                     | Recruiting                                                                                                        |                                                                                                                   | All                                                                                                               | 18 Years and older Â  (Adult, Older Adult)                                                                        |                                                                                                                   | 500                                                                                                               | May 7, 2020                                                                                                       | June 2020                                                                                                         | May 14, 2020                                                                                                      | Department of Infectiology, Raymond PoincarÃ© Hospital, APHP, Garches, France                                     | https://ClinicalTrials.gov/show/NCT04364698                                                                       | France                                                                                                            |                                                                                                                   |\n",
       "| 3                                                                                                                 | Decitabine for Coronavirus (COVID-19) Pneumonia- Acute Respiratory Distress Syndrome (ARDS) Treatment: DART Trial | Recruiting                                                                                                        | Drug: Decitabine|Other: Placebo Saline                                                                            | All                                                                                                               | 18 Years and older Â  (Adult, Older Adult)                                                                        | Phase 2                                                                                                           |  40                                                                                                               | September 14, 2020                                                                                                | July 2021                                                                                                         | September 25, 2020                                                                                                | Johns Hopkins University, Baltimore, Maryland, United States                                                      | https://ClinicalTrials.gov/show/NCT04482621                                                                       | United States                                                                                                     | Decitabine                                                                                                        |\n",
       "| 4                                                                                                                 | COVID-19 Surveillance Based on Smart Wearable Device                                                              | Not yet recruiting                                                                                                |                                                                                                                   | All                                                                                                               | 18 Years to 75 Years Â  (Adult, Older Adult)                                                                      |                                                                                                                   | 200                                                                                                               | July 1, 2020                                                                                                      | March 10, 2021                                                                                                    | July 7, 2020                                                                                                      | Peking University First Hospital, Beijing, Beijing, China                                                         | https://ClinicalTrials.gov/show/NCT04459637                                                                       | China                                                                                                             |                                                                                                                   |\n",
       "| 5                                                                                                                 | A Phase 2 Trial of Infliximab in Coronavirus Disease 2019 (COVID-19).                                             | Recruiting                                                                                                        | Drug: Infliximab                                                                                                  | All                                                                                                               | 18 Years and older Â  (Adult, Older Adult)                                                                        | Phase 2                                                                                                           |  17                                                                                                               | June 1, 2020                                                                                                      | December 2020                                                                                                     | June 11, 2020                                                                                                     | Tufts Medical Center, Boston, Massachusetts, United States                                                        | https://ClinicalTrials.gov/show/NCT04425538                                                                       | United States                                                                                                     | Infliximab                                                                                                        |\n",
       "| 6                                                                                                                 | Safety & Performance Evaluation of Seraph 100 in Treatment of Pts With COVID-19                                   | Not yet recruiting                                                                                                | Device: Seraph 100                                                                                                | All                                                                                                               | 18 Years to 90 Years Â  (Adult, Older Adult)                                                                      | Not Applicable                                                                                                    |  42                                                                                                               | December 15, 2020                                                                                                 | April 15, 2021                                                                                                    | November 27, 2020                                                                                                 | Carla Kikken-Jussen, Vaals, Limburg, Netherlands                                                                  | https://ClinicalTrials.gov/show/NCT04547257                                                                       | Netherlands                                                                                                       |                                                                                                                   |\n",
       "\n"
      ],
      "text/plain": [
       "  X\n",
       "1 1\n",
       "2 2\n",
       "3 3\n",
       "4 4\n",
       "5 5\n",
       "6 6\n",
       "  Title                                                                                                            \n",
       "1 Duvelisib to Combat COVID-19                                                                                     \n",
       "2 Observational Cohort of COVID-19 Patients at Raymond-Poincare                                                    \n",
       "3 Decitabine for Coronavirus (COVID-19) Pneumonia- Acute Respiratory Distress Syndrome (ARDS) Treatment: DART Trial\n",
       "4 COVID-19 Surveillance Based on Smart Wearable Device                                                             \n",
       "5 A Phase 2 Trial of Infliximab in Coronavirus Disease 2019 (COVID-19).                                            \n",
       "6 Safety & Performance Evaluation of Seraph 100 in Treatment of Pts With COVID-19                                  \n",
       "  Status            \n",
       "1 Recruiting        \n",
       "2 Recruiting        \n",
       "3 Recruiting        \n",
       "4 Not yet recruiting\n",
       "5 Recruiting        \n",
       "6 Not yet recruiting\n",
       "  Interventions                                                  Gender\n",
       "1 Drug: Duvelisib|Procedure: Peripheral blood draw|Drug: Placebo All   \n",
       "2                                                                All   \n",
       "3 Drug: Decitabine|Other: Placebo Saline                         All   \n",
       "4                                                                All   \n",
       "5 Drug: Infliximab                                               All   \n",
       "6 Device: Seraph 100                                             All   \n",
       "  Age                                          Phases         Enrollment\n",
       "1 18 Years and older Â  (Adult, Older Adult)   Phase 2         28       \n",
       "2 18 Years and older Â  (Adult, Older Adult)                  500       \n",
       "3 18 Years and older Â  (Adult, Older Adult)   Phase 2         40       \n",
       "4 18 Years to 75 Years Â  (Adult, Older Adult)                200       \n",
       "5 18 Years and older Â  (Adult, Older Adult)   Phase 2         17       \n",
       "6 18 Years to 90 Years Â  (Adult, Older Adult) Not Applicable  42       \n",
       "  Start.Date         Completion.Date Last.Update.Posted\n",
       "1 October 12, 2020   April 30, 2022  November 9, 2020  \n",
       "2 May 7, 2020        June 2020       May 14, 2020      \n",
       "3 September 14, 2020 July 2021       September 25, 2020\n",
       "4 July 1, 2020       March 10, 2021  July 7, 2020      \n",
       "5 June 1, 2020       December 2020   June 11, 2020     \n",
       "6 December 15, 2020  April 15, 2021  November 27, 2020 \n",
       "  Locations                                                                     \n",
       "1 Washington University School of Medicine, Saint Louis, Missouri, United States\n",
       "2 Department of Infectiology, Raymond PoincarÃ© Hospital, APHP, Garches, France \n",
       "3 Johns Hopkins University, Baltimore, Maryland, United States                  \n",
       "4 Peking University First Hospital, Beijing, Beijing, China                     \n",
       "5 Tufts Medical Center, Boston, Massachusetts, United States                    \n",
       "6 Carla Kikken-Jussen, Vaals, Limburg, Netherlands                              \n",
       "  URL                                         MapCountry    Drugonly         \n",
       "1 https://ClinicalTrials.gov/show/NCT04372602 United States Duvelisib|Placebo\n",
       "2 https://ClinicalTrials.gov/show/NCT04364698 France                         \n",
       "3 https://ClinicalTrials.gov/show/NCT04482621 United States Decitabine       \n",
       "4 https://ClinicalTrials.gov/show/NCT04459637 China                          \n",
       "5 https://ClinicalTrials.gov/show/NCT04425538 United States Infliximab       \n",
       "6 https://ClinicalTrials.gov/show/NCT04547257 Netherlands                    "
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "# Read the cleaned data\n",
    "data <- read.csv(\"MyCleanData.csv\")\n",
    "head(data)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Add empty columns of each age group\n",
    "data['AgeChild'] <- NA\n",
    "data['AgeAdult'] <- NA\n",
    "data['AgeOlderAdult'] <- NA"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Fill the newly created columns with Yes's and No's according to the Age column\n",
    "data$AgeChild <- ifelse(grepl(\"Child\", data$Age),\"Yes\", \"No\")\n",
    "data$AgeAdult <- ifelse(grepl(\"Adult\", data$Age),\"Yes\", \"No\")\n",
    "data$AgeOlderAdult <- ifelse(grepl(\"Older Adult\", data$Age),\"Yes\", \"No\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "0"
      ],
      "text/latex": [
       "0"
      ],
      "text/markdown": [
       "0"
      ],
      "text/plain": [
       "[1] 0"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "0"
      ],
      "text/latex": [
       "0"
      ],
      "text/markdown": [
       "0"
      ],
      "text/plain": [
       "[1] 0"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "0"
      ],
      "text/latex": [
       "0"
      ],
      "text/markdown": [
       "0"
      ],
      "text/plain": [
       "[1] 0"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "# Check for missing values\n",
    "sum(is.na(data$AgeChild))\n",
    "sum(is.na(data$AgeAult))\n",
    "sum(is.na(data$AgeOlderAdult))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Create a new data frame consisting of related variables\n",
    "age_data <- select(data, MapCountry, AgeChild, AgeAdult, AgeOlderAdult)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<table>\n",
       "<thead><tr><th scope=col>MapCountry</th><th scope=col>AgeChild</th><th scope=col>AgeAdult</th><th scope=col>AgeOlderAdult</th></tr></thead>\n",
       "<tbody>\n",
       "\t<tr><td>United States            </td><td>No                       </td><td>Yes                      </td><td>Yes                      </td></tr>\n",
       "\t<tr><td>France                   </td><td>No                       </td><td>Yes                      </td><td>Yes                      </td></tr>\n",
       "\t<tr><td>United States            </td><td>No                       </td><td>Yes                      </td><td>Yes                      </td></tr>\n",
       "\t<tr><td>China                    </td><td>No                       </td><td>Yes                      </td><td>Yes                      </td></tr>\n",
       "\t<tr><td>United States            </td><td>No                       </td><td>Yes                      </td><td>Yes                      </td></tr>\n",
       "\t<tr><td>Netherlands              </td><td>No                       </td><td>Yes                      </td><td>Yes                      </td></tr>\n",
       "\t<tr><td>Undefined                </td><td>No                       </td><td>Yes                      </td><td>Yes                      </td></tr>\n",
       "\t<tr><td>India                    </td><td>No                       </td><td>Yes                      </td><td>Yes                      </td></tr>\n",
       "\t<tr><td>Iran, Islamic Republic of</td><td>Yes                      </td><td>Yes                      </td><td>Yes                      </td></tr>\n",
       "\t<tr><td>Turkey                   </td><td>No                       </td><td>Yes                      </td><td>Yes                      </td></tr>\n",
       "</tbody>\n",
       "</table>\n"
      ],
      "text/latex": [
       "\\begin{tabular}{r|llll}\n",
       " MapCountry & AgeChild & AgeAdult & AgeOlderAdult\\\\\n",
       "\\hline\n",
       "\t United States             & No                        & Yes                       & Yes                      \\\\\n",
       "\t France                    & No                        & Yes                       & Yes                      \\\\\n",
       "\t United States             & No                        & Yes                       & Yes                      \\\\\n",
       "\t China                     & No                        & Yes                       & Yes                      \\\\\n",
       "\t United States             & No                        & Yes                       & Yes                      \\\\\n",
       "\t Netherlands               & No                        & Yes                       & Yes                      \\\\\n",
       "\t Undefined                 & No                        & Yes                       & Yes                      \\\\\n",
       "\t India                     & No                        & Yes                       & Yes                      \\\\\n",
       "\t Iran, Islamic Republic of & Yes                       & Yes                       & Yes                      \\\\\n",
       "\t Turkey                    & No                        & Yes                       & Yes                      \\\\\n",
       "\\end{tabular}\n"
      ],
      "text/markdown": [
       "\n",
       "| MapCountry | AgeChild | AgeAdult | AgeOlderAdult |\n",
       "|---|---|---|---|\n",
       "| United States             | No                        | Yes                       | Yes                       |\n",
       "| France                    | No                        | Yes                       | Yes                       |\n",
       "| United States             | No                        | Yes                       | Yes                       |\n",
       "| China                     | No                        | Yes                       | Yes                       |\n",
       "| United States             | No                        | Yes                       | Yes                       |\n",
       "| Netherlands               | No                        | Yes                       | Yes                       |\n",
       "| Undefined                 | No                        | Yes                       | Yes                       |\n",
       "| India                     | No                        | Yes                       | Yes                       |\n",
       "| Iran, Islamic Republic of | Yes                       | Yes                       | Yes                       |\n",
       "| Turkey                    | No                        | Yes                       | Yes                       |\n",
       "\n"
      ],
      "text/plain": [
       "   MapCountry                AgeChild AgeAdult AgeOlderAdult\n",
       "1  United States             No       Yes      Yes          \n",
       "2  France                    No       Yes      Yes          \n",
       "3  United States             No       Yes      Yes          \n",
       "4  China                     No       Yes      Yes          \n",
       "5  United States             No       Yes      Yes          \n",
       "6  Netherlands               No       Yes      Yes          \n",
       "7  Undefined                 No       Yes      Yes          \n",
       "8  India                     No       Yes      Yes          \n",
       "9  Iran, Islamic Republic of Yes      Yes      Yes          \n",
       "10 Turkey                    No       Yes      Yes          "
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "# Check the data frame\n",
    "head(age_data,10)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Remove Undefined countries from the data\n",
    "age_data <- subset(age_data, MapCountry != \"Undefined\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "\n",
       "  No  Yes \n",
       "3007  646 "
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/plain": [
       "\n",
       "  No  Yes \n",
       "  44 3609 "
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/plain": [
       "\n",
       "  No  Yes \n",
       " 289 3364 "
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "# Count the occurences of Yes and No in each Age Group column\n",
    "table(age_data$AgeChild)\n",
    "table(age_data$AgeAdult)\n",
    "table(age_data$AgeOlderAdult)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "\n",
       " United States         France          Italy United Kingdom          China \n",
       "           736            540            172            170            161 \n",
       "         Egypt          Spain         Canada         Turkey         Brazil \n",
       "           145            137            136            130            115 "
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "# Find the top 10 countries with the most recorded trials\n",
    "sort(table(age_data$MapCountry), decreasing = TRUE)[1:10]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Count Yes's in each age group in the United States\n",
    "age_dataUSA <- filter(age_data, MapCountry == \"United States\")\n",
    "ageUSA_Child <- sum(age_dataUSA$AgeChild == \"Yes\")\n",
    "ageUSA_Adult <- sum(age_dataUSA$AgeAdult == \"Yes\")\n",
    "ageUSA_OlderAdult <- sum(age_dataUSA$AgeOlderAdult == \"Yes\")\n",
    "\n",
    "# Count Yes's in each age group in the France\n",
    "age_dataFRA <- filter(age_data, MapCountry == \"France\")\n",
    "ageFRA_Child <- sum(age_dataFRA$AgeChild == \"Yes\")\n",
    "ageFRA_Adult <- sum(age_dataFRA$AgeAdult == \"Yes\")\n",
    "ageFRA_OlderAdult <- sum(age_dataFRA$AgeOlderAdult == \"Yes\")\n",
    "\n",
    "# Count Yes's in each age group in the Italy\n",
    "age_dataITA <- filter(age_data, MapCountry == \"Italy\")\n",
    "ageITA_Child <- sum(age_dataITA$AgeChild == \"Yes\")\n",
    "ageITA_Adult <- sum(age_dataITA$AgeAdult == \"Yes\")\n",
    "ageITA_OlderAdult <- sum(age_dataITA$AgeOlderAdult == \"Yes\")\n",
    "\n",
    "# Count Yes's in each age group in the United Kingdom\n",
    "age_dataUK <- filter(age_data, MapCountry == \"United Kingdom\")\n",
    "ageUK_Child <- sum(age_dataUK$AgeChild == \"Yes\")\n",
    "ageUK_Adult <- sum(age_dataUK$AgeAdult == \"Yes\")\n",
    "ageUK_OlderAdult <- sum(age_dataUK$AgeOlderAdult == \"Yes\")\n",
    "\n",
    "# Count Yes's in each age group in the China\n",
    "age_dataCHI <- filter(age_data, MapCountry == \"China\")\n",
    "ageCHI_Child <- sum(age_dataCHI$AgeChild == \"Yes\")\n",
    "ageCHI_Adult <- sum(age_dataCHI$AgeAdult == \"Yes\")\n",
    "ageCHI_OlderAdult <- sum(age_dataCHI$AgeOlderAdult == \"Yes\")\n",
    "\n",
    "# Count Yes's in each age group in the Egypt\n",
    "age_dataEGY <- filter(age_data, MapCountry == \"Egypt\")\n",
    "ageEGY_Child <- sum(age_dataEGY$AgeChild == \"Yes\")\n",
    "ageEGY_Adult <- sum(age_dataEGY$AgeAdult == \"Yes\")\n",
    "ageEGY_OlderAdult <- sum(age_dataEGY$AgeOlderAdult == \"Yes\")\n",
    "\n",
    "# Count Yes's in each age group in the Spain\n",
    "age_dataSPA <- filter(age_data, MapCountry == \"Spain\")\n",
    "ageSPA_Child <- sum(age_dataSPA$AgeChild == \"Yes\")\n",
    "ageSPA_Adult <- sum(age_dataSPA$AgeAdult == \"Yes\")\n",
    "ageSPA_OlderAdult <- sum(age_dataSPA$AgeOlderAdult == \"Yes\")\n",
    "\n",
    "# Count Yes's in each age group in the Canada\n",
    "age_dataCAN <- filter(age_data, MapCountry == \"Canada\")\n",
    "ageCAN_Child <- sum(age_dataCAN$AgeChild == \"Yes\")\n",
    "ageCAN_Adult <- sum(age_dataCAN$AgeAdult == \"Yes\")\n",
    "ageCAN_OlderAdult <- sum(age_dataCAN$AgeOlderAdult == \"Yes\")\n",
    "\n",
    "# Count Yes's in each age group in the Turkey\n",
    "age_dataTUR <- filter(age_data, MapCountry == \"Turkey\")\n",
    "ageTUR_Child <- sum(age_dataTUR$AgeChild == \"Yes\")\n",
    "ageTUR_Adult <- sum(age_dataTUR$AgeAdult == \"Yes\")\n",
    "ageTUR_OlderAdult <- sum(age_dataTUR$AgeOlderAdult == \"Yes\")\n",
    "\n",
    "# Count Yes's in each age group in the Brazil\n",
    "age_dataBRA <- filter(age_data, MapCountry == \"Brazil\")\n",
    "ageBRA_Child <- sum(age_dataBRA$AgeChild == \"Yes\")\n",
    "ageBRA_Adult <- sum(age_dataBRA$AgeAdult == \"Yes\")\n",
    "ageBRA_OlderAdult <- sum(age_dataBRA$AgeOlderAdult == \"Yes\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Calculate the number of recorded trials done by the top 10 countries\n",
    "n1 <- nrow(age_dataUSA)\n",
    "n2 <- nrow(age_dataFRA)\n",
    "n3 <- nrow(age_dataITA)\n",
    "n4 <- nrow(age_dataUK)\n",
    "n5 <- nrow(age_dataCHI)\n",
    "n6 <- nrow(age_dataEGY)\n",
    "n7 <- nrow(age_dataSPA)\n",
    "n8 <- nrow(age_dataCAN)\n",
    "n9 <- nrow(age_dataTUR)\n",
    "n10 <- nrow(age_dataBRA)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Visualization"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "There are 646 child trials, 3609 adult trials, and 3364 older adult trials.\n",
    "\n",
    "Now, let's visualize the distribution of age group among all countries that did clinical trials."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "iVBORw0KGgoAAAANSUhEUgAAA0gAAANICAMAAADKOT/pAAAAjVBMVEUAAAAUMT0bQlIgTmIk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\nAABJRU5ErkJggg==",
      "text/plain": [
       "plot without title"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "# Create data frame for the visualization\n",
    "data <- data.frame(\n",
    "  category=c(\"Child\", \"Adult\", \"Older Adult\"),\n",
    "  count=c(646, 3609, 3364)\n",
    ")\n",
    " \n",
    "# Compute percentages\n",
    "data$fraction <- data$count / sum(data$count)\n",
    "\n",
    "# Compute the cumulative percentages (top of each rectangle)\n",
    "data$ymax <- cumsum(data$fraction)\n",
    "\n",
    "# Compute the bottom of each rectangle\n",
    "data$ymin <- c(0, head(data$ymax, n=-1))\n",
    "\n",
    "# Compute label position\n",
    "data$labelPosition <- (data$ymax + data$ymin) / 2\n",
    "\n",
    "# Compute a good label\n",
    "data$label <- paste0(data$category, \"\\n value: \", data$count)\n",
    "\n",
    "# Make the plot\n",
    "ggplot(data, aes(ymax=ymax, ymin=ymin, xmax=4, xmin=3.5, fill=category)) +\n",
    "  geom_rect() +\n",
    "  geom_label( x=3.75, aes(y=labelPosition, label=label), size=5) +\n",
    "  scale_fill_brewer(palette=4) +\n",
    "  coord_polar(theta=\"y\") +\n",
    "  xlim(c(2, 4)) +\n",
    "  theme_void() +\n",
    "  theme(legend.position = \"none\")"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Now, let's visualize the distribution of trials in the top 10 countries with the most clinical trials."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 17,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "iVBORw0KGgoAAAANSUhEUgAAA0gAAANICAMAAADKOT/pAAAAM1BMVEUzMzNxcXGGhoaWlpaj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\nSIAAIQEChAQIEBIgQEiAACEBAv8DQ6R4ng60KQwAAAAASUVORK5CYII=",
      "text/plain": [
       "plot without title"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "# Create dataset\n",
    "id <- seq(1:10)\n",
    "individual <- c(\"United States\",\"France\",\"Italy\",\"United Kingdom\",\n",
    "                   \"China\",\"Egypt\",\"Spain\",\"Canada\",\"Turkey\",\"Brazil\")\n",
    "value <- c(736,540,172,170,161,145,137,136,130,115) # Values taken from previous calculation\n",
    "data <- data.frame(id,individual,value)\n",
    "\n",
    "# Get the name and the y position of each label\n",
    "label_data <- data\n",
    " \n",
    "# calculate the ANGLE of the labels\n",
    "number_of_bar <- nrow(label_data)\n",
    "angle <-  90 - 360 * (label_data$id-0.5) /number_of_bar\n",
    "# Substracted 0.5 because the letter must have the angle of the center of the bars. \n",
    "# Not extreme right(1) or extreme left (0).\n",
    " \n",
    "# calculate the alignment of labels: right or left\n",
    "# If I am on the left part of the plot, my labels have currently an angle < -90\n",
    "label_data$hjust<-ifelse( angle < -90, 1, 0)\n",
    " \n",
    "# flip angle BY to make them readable\n",
    "label_data$angle<-ifelse(angle < -90, angle+180, angle)\n",
    " \n",
    "# Start the plot\n",
    "p1 <- ggplot(data, aes(x=as.factor(id), y=value)) + \n",
    "# Note that id is a factor. If x is numeric, there is some space between the first bar\n",
    "  \n",
    "# This add the bars with a blue color\n",
    "geom_bar(stat=\"identity\", fill=alpha(\"skyblue\", 0.7)) +\n",
    "  \n",
    "# Limits of the plot = very important. The negative value controls the size of the inner circle, \n",
    "# the positive one is useful to add size over each bar.\n",
    "ylim(-150,900) +\n",
    "  \n",
    "# Custom the theme: no axis title and no cartesian grid\n",
    "theme_minimal() +\n",
    "theme(\n",
    "    axis.text = element_blank(),\n",
    "    axis.title = element_blank(),\n",
    "    panel.grid = element_blank(),\n",
    "    plot.margin = unit(rep(-1,4), \"cm\") # Adjust the margin to make in sort labels are not truncated!\n",
    "  ) +\n",
    "  \n",
    "# This makes the coordinate polar instead of cartesian.\n",
    "coord_polar(start = 0) +\n",
    "  \n",
    "# Add the labels, using the label_data dataframe that we have created before\n",
    "geom_text(data=label_data, aes(x=id, y=value+10, label=individual, hjust=hjust), \n",
    "          color=\"black\", fontface=\"bold\",alpha=0.8, size=2.7, angle= label_data$angle, inherit.aes = FALSE ) \n",
    "\n",
    "show(p1)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Now, let's visualize the distribution of age group in each top 10 countries with the most clinical trials."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 16,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Warning message:\n",
      "\"Removed 9 rows containing missing values (position_stack).\"Warning message:\n",
      "\"Removed 9 rows containing missing values (position_stack).\"Warning message:\n",
      "\"Removed 9 rows containing missing values (geom_text).\""
     ]
    },
    {
     "data": {
      "image/png": "iVBORw0KGgoAAAANSUhEUgAAA0gAAANICAMAAADKOT/pAAAAn1BMVEUKCgoNKRUWFhYXFxca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\nYAAiAcAARAKAAYgEAAMQCQAG/j/WTAYFuVbClAAAAABJRU5ErkJggg==",
      "text/plain": [
       "plot without title"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "# Create dataset\n",
    "id <- seq(1:30)\n",
    "individual <- c(\"United States\",\"France\",\"Italy\",\"United Kingdom\",\n",
    "                \"China\",\"Egypt\",\"Spain\",\"Canada\",\"Turkey\",\"Brazil\",\n",
    "                \"United States\",\"France\",\"Italy\",\"United Kingdom\",\n",
    "                \"China\",\"Egypt\",\"Spain\",\"Canada\",\"Turkey\",\"Brazil\",\n",
    "                \"United States\",\"France\",\"Italy\",\"United Kingdom\",\n",
    "                \"China\",\"Egypt\",\"Spain\",\"Canada\",\"Turkey\",\"Brazil\")\n",
    "group <- c( rep('Child', 10), rep('Adult', 10), rep('Older Adult', 10))\n",
    "value <- c(86,104,28,46,39,61,32,29,21,18,\n",
    "           729,529,171,164,159,145,137,132,124,115,\n",
    "           700,508,163,149,141,118,135,123,88,110)\n",
    "data <- data.frame(id,individual,group,value)\n",
    "\n",
    "# Set a number of 'empty bar' to add at the end of each group\n",
    "empty_bar <- 3\n",
    "to_add <- data.frame( matrix(NA, empty_bar*nlevels(data$group), ncol(data)) )\n",
    "colnames(to_add) <- colnames(data)\n",
    "to_add$group <- rep(levels(data$group), each=empty_bar)\n",
    "data <- rbind(data, to_add)\n",
    "data <- data %>% arrange(group)\n",
    "data$id <- seq(1, nrow(data))\n",
    " \n",
    "# Get the name and the y position of each label\n",
    "label_data <- data\n",
    "number_of_bar <- nrow(label_data)\n",
    "angle <- 90 - 360 * (label_data$id-0.5) /number_of_bar\n",
    "# Substracted 0.5 because the letter must have the angle of the center of the bars.\n",
    "# Not extreme right(1) or extreme left (0)\n",
    "label_data$hjust <- ifelse( angle < -90, 1, 0)\n",
    "label_data$angle <- ifelse(angle < -90, angle+180, angle)\n",
    " \n",
    "# prepare a data frame for base lines\n",
    "base_data <- data %>% \n",
    "  group_by(group) %>% \n",
    "  summarize(start=min(id), end=max(id) - empty_bar) %>% \n",
    "  rowwise() %>% \n",
    "  mutate(title=mean(c(start, end)))\n",
    " \n",
    "# prepare a data frame for grid (scales)\n",
    "grid_data <- base_data\n",
    "grid_data$end <- grid_data$end[ c( nrow(grid_data), 1:nrow(grid_data)-1)] + 1\n",
    "grid_data$start <- grid_data$start - 1\n",
    "grid_data <- grid_data[-1,]\n",
    " \n",
    "# Make the plot\n",
    "p3 <- ggplot(data, aes(x=as.factor(id), y=value, fill=group)) +       \n",
    "# Note that id is a factor. If x is numeric, there is some space between the first bar\n",
    "  \n",
    "geom_bar(aes(x=as.factor(id), y=value, fill=group), stat=\"identity\", alpha=0.5) +\n",
    "  \n",
    "geom_bar(aes(x=as.factor(id), y=value, fill=group), stat=\"identity\", alpha=0.5) +\n",
    "ylim(-150,750) +\n",
    "theme_minimal() +\n",
    "theme(\n",
    "    legend.position = \"none\",\n",
    "    axis.text = element_blank(),\n",
    "    axis.title = element_blank(),\n",
    "    panel.grid = element_blank(),\n",
    "    plot.margin = unit(rep(-1,4), \"cm\") \n",
    "  ) +\n",
    "  coord_polar() + \n",
    "  geom_text(data=label_data, aes(x=id, y=value+10, label=individual, hjust=hjust), color=\"black\", \n",
    "            fontface=\"bold\",alpha=0.7, size=3.0, angle= label_data$angle, inherit.aes = FALSE ) +\n",
    "  \n",
    "# Add base line information\n",
    "geom_segment(data=base_data, aes(x = start, y = -5, xend = end, yend = -5), colour = \"black\", \n",
    "               alpha=0.8, size=0.7 , inherit.aes = FALSE )  +\n",
    "geom_text(data=base_data, aes(x = title, y = -18, label=group), hjust=c(1,1,0), colour = \"black\", \n",
    "            alpha=0.8, size=3, fontface=\"bold\", inherit.aes = FALSE)\n",
    "\n",
    "show(p3)"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "R",
   "language": "R",
   "name": "ir"
  },
  "language_info": {
   "codemirror_mode": "r",
   "file_extension": ".r",
   "mimetype": "text/x-r-source",
   "name": "R",
   "pygments_lexer": "r",
   "version": "3.6.1"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 4
}
